2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Cell Expansion, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Chimeric Antigen Receptor, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

284 IL-7/IL-7Rα reprogramming primes sting signaling in CAR-NK cells and unlocks coordinated innate-adaptive antitumor immunity

Andreia Maia, MS, PhD, Fuguo Liu, PhD2, Mubin Tarannum3, Sara Piccinelli4, Eric de Sousa, PhD5, Caroline Fahey6, Alexandra Qui7, Fabian Göllner8, Tereza Kochs9, Veronica W Hui10, Shaobo Yang11, Grace Caroline Birch, PhD12, Mila Stanojevic13, Maily Nyugen14, Eden Bobilev15, Marco Campisi16, Ian Gillanders17, Bartosz Grzywacz18, Alaa Kassim Ali, PhD19, Remy Dulery, MD, PhD20, Edward Briercheck, MD PhD21, Roman Shapiro, MD22, Eric L Smith, Director of Translation, Immune Effector Cell Therapies23, John Koreth, MD,MBBS,PhD,DPhil24, Robert J Soiffer, MD25, Catherine J. Wu, MD26, Jerome Ritz, MD27, David A. Barbie28, Rizwan Romee, MD29
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Fundação Champalimaud, Lisboa, Portugal
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
27 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
28 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
29 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Background. CAR-T and CAR-NK cell therapies remain limited in solid and resistant hematologic malignancies by an immunosuppressive tumor microenvironment (TME) and poor effector cell persistence. Because IL-7 promotes T cell proliferation while preventing exhaustion, we investigated IL-7 as a strategy to modulate the TME. However, mature NK cells downregulate IL-7Rα and are unresponsive to IL-7. To overcome this, we engineered CAR-NK cells to secrete IL-7 and express IL-7Rα, enhancing NK activation while stimulating bystander T cells. The STING pathway regulates antitumor immunity via type I interferon and inflammatory cytokines. Unexpectedly, IL-7/IL-7Rα reprogramming engaged intrinsic STING signaling in engineered NK cells, revealing a targetable innate-sensing axis for combinatorial activation.

Methods. We generated CAR-NK cells (NK-0) targeting CD70 or Mesothelin (MSLN) and further engineered them to secrete IL-7 (NK-7) or secrete IL-7 plus express IL-7Rα (NK-7R). Proliferation and function were evaluated by CellTrace Violet assays, cytotoxic assays, and cytokine secretion. Effects of IL-7/IL-7Rα on downstream pathways were assessed by bulk RNA-seq and western blot. CAR-NK cells were stimulated with ADU-S100 (STING agonist), and antitumor function was evaluated in vitro and in vivo mouse models.

 

Results. Engineered NK cells showed high CAR transduction (<70%), and NK-7R displayed higher IL-7Rα expression (47.3% vs 2.5% for NK-0 and 0.5% for NK-7, p<0.0001). NK-7 and NK-7R secreted high IL-7 (759.8 and 1349.9 pg/mL) vs NK-0 (55.3 pg/mL, p=0.0033).

NK-7R showed increased cytotoxicity (61.4% vs 52.3% for NK-7, p=0.712 and 49.8% for NK-0, p=0.002) against MSLN+ tumor cells (2:1 ratio), with 3.9-fold higher IFNg (0.9 for NK-7, p=0.0002; 1 for NK-0, p=0.0005). NK-7R showed superior proliferation (1.9) vs NK-0 (1.1, p=0.03) in media without IL-2/IL-15 support. In NSG-Tg(Hu-IL15) mice (n=5) given CAR-NK cells intravenously (IV), NK-7R showed higher hCD45+ infiltration than NK-0 by two weeks, including bone marrow (0.23% vs 0.05%, p=0.0039), liver (2.17% vs 0.04%, p=0.0477), spleen (1.40% vs 0.05%, p=0.0367), and blood (1.38% vs 0.27%, p=0.0280).

CD19-T cells also showed increased cytotoxicity against lymphoma (Raji) cells when co-cultured with IL-7-secreting CAR-NK cells (0.53 for NK-7R (normalized to target) vs 0.31 for CD19-T (p=0.0346), 0.36 for CD19-T + NK-0 and 0.56 for CD19-T + NK-7). In NGS-TG (Hu-IL15) mice (n=5), co-administration of CD19-T cells + NK-7R resulted in superior tumor control of Raji cells on day 21, as measured by area under the curve (AUC) of total flux [p/s]: 2.14 x 108 for CD19-T + NK-7R, compared to 2.15 x 109 for CD19-T + NK-7, 4.41 x 109 for CD19-T plus NK-0, and 2.36 x 109 for CD19-T cells alone.

Mechanistically, bulk RNA-seq showed upregulated STING pathway genes in NK-7R vs NK-7 and NK-0, confirmed by western blot (CXCL10, STAT1, IRF3, TBK1). With ADU-S100 stimulation, NK-7R cells showed superior cytotoxicity against MSLN+ cells (36.3%) vs stimulated NK-7 (18.3%, p=0.0186) or unstimulated NK-7R cells (18.5%, p=0.0021), showing STING agonism selectively potentiates the antitumor effect of IL-7/IL-7Rα engineering.

To test this synergy in vivo, NSG-TG(Hu-IL15) mice (n=8) were implanted subcutaneously with ASPC1 (MSLN+) tumor cells, HUVEC, and fibroblasts to generate vascularized tumors. At 100-150 mm3, mice received 5 x 106 CAR-NK cells (IV) with or without 50 µg of intratumoral ADU-S100, repeated one week later. At endpoint, tumors were smaller with NK-7R (327.7 mm3) than NK-0 (483.2 mm3) or untreated controls (632.3 mm3), and smallest with NK-7R + ADU-S100 (168.0 mm3) vs NK-0 + ADU-S100 (273.2mm3, p=0.0392), and ADU-S100 alone (327.8mm3, p=0.0925). NK-7R + ADU-S100 also achieved the greatest intratumoral NK cell infiltration (0.159%) vs NK-0 + ADU-S100 (0.051%) or ADU-S100 alone (0.020%, p=0.0254), with elevated intratumoral CXCL10 and IL-7 but low systemic cytokines.

 

Conclusion. IL-7/IL-7Rα reprogramming endows CAR-NK cells with enhanced proliferative and cytotoxic function while stimulating bystander T cells. We further identify a synergy between IL-7/IL-7Rα signaling and STING pathway activation that drives a stronger antitumor response, establishing IL-7/IL-7Rα engineering as a strategy to reprogram CAR-NK cells into durable orchestrators of coordinated innate-adaptive immunity in resistant malignancies.

Andreia Maia, MS, PhD: No relevant conflicts of interest to declare.